Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10303–10315 | Cite as

A possible role of GDDR in the development of Helicobacter pylori-associated gastric cancer

  • Zhanwei Zhao
  • Fei Wang
  • Cheng Fang
  • Gang Wang
  • Jianbo Shuang
  • Guanghui Chu
  • Sijun Hu
  • Lin Chen
  • Jianjun Du
Original Article
  • 181 Downloads

Abstract

Helicobacter pylori (H. pylori) infection plays an important part in the development of gastric carcinoma. GDDR has been confirmed as a tumor suppressor gene in gastric tumorigenesis. However, the underlying mechanism of GDDR in H. pylori-induced carcinogenesis is not well known. The aim of this study is to investigate the clinicopathological significance and possible molecular mechanism of GDDR in gastric cancer associated with H. pylori. Western blot, real-time quantitative PCR (qRT-PCR), and immunohistochemistry were used to detect the expression level of GDDR with or without H. pylori infection. The function and possible related molecular mechanisms of GDDR were further explored in vitro and in vivo. The variability of GDDR expression appeared in the early stage of gastric carcinogenesis with positive H. pylori infection status. GDDR might inhibit the progression of normal gastric epithelial cells to cancer cells by suppressing NF-kappaB signaling pathway, which in turn could be regulated by H. pylori infection. Our results suggested, for the first time, that the gradual change in GDDR expression might not only be directly related to H. pylori infection but also be an early molecular event in the development of gastric carcinoma.

Keywords

GDDR Helicobacter pylori Gastric cancer Precancerous lesions NF-KappaB 

Notes

Acknowledgments

We are grateful to Dr. Sijun Hu for the SS1 H. pylori, Dr. Zhongshu Pu for the excellent guidance with regards to the statistics, and Ling Chen and Yong Guo of the pathology department.

Compliance with ethical standards

Conflicts of interest

None

Funding

This study was funded by the National Science Foundation of China: No. 30471698.

Consent for Publication

The protocols is that all samples (a total of 440 tissue samples included in this study) were obtained from patients who gave informed consent to use excess pathological specimens for research purposes only.

The protocols used in the study were approved by the Xijing Hospital's Protection of Human Subjects Committee, the Fourth Military Medical University, Xi'an, China.

References

  1. 1.
    Shen L et al. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14(12):e535–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40.PubMedGoogle Scholar
  3. 3.
    Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt B):1–441Google Scholar
  4. 4.
    Ford AC et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ. 2014;348:g3174.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Uemura N et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Bornschein J, Malfertheiner P. Helicobacter pylori and gastric cancer. Dig Dis. 2014;32(3):249–64.CrossRefPubMedGoogle Scholar
  7. 7.
    Bessede E et al. Helicobacter pylori infection and stem cells at the origin of gastric cancer. Oncogene 2014.Google Scholar
  8. 8.
    Jin R et al. NF-kappaB gene signature predicts prostate cancer progression. Cancer Res 2014.Google Scholar
  9. 9.
    Hao Q et al. FOXP3 inhibits NF-kappaB activity and hence COX2 expression in gastric cancer cells. Cell Signal. 2014;26(3):564–9.CrossRefPubMedGoogle Scholar
  10. 10.
    [10]. Kang, S.R., et al., Suppressive effect on lipopolysaccharide-induced proinflammatory mediators by Citrus aurantium L. in macrophage RAW 264.7 cells via NF-kappaB signal pathway. Evid Based Complement Alternat Med 2011;2011.Google Scholar
  11. 11.
    Li L et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappaB activation. PLoS ONE. 2014;9(4):e95912.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Brandt S et al. NF-kappaB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci U S A. 2005;102(26):9300–5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Yanai A et al. Activation of IkappaB kinase and NF-kappaB is essential for Helicobacter pylori-induced chronic gastritis in Mongolian gerbils. Infect Immun. 2008;76(2):781–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim DJ et al. Helicobacter pylori proinflammatory protein up-regulates NF-kappaB as a cell-translocating Ser/Thr kinase. Proc Natl Acad Sci U S A. 2010;107(50):21418–23.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kouznetsova I et al. Biosynthesis of gastrokine-2 in the human gastric mucosa: restricted spatial expression along the antral gland axis and differential interaction with TFF1, TFF2 and mucins. Cell Physiol Biochem. 2007;20(6):899–908.CrossRefPubMedGoogle Scholar
  16. 16.
    Chu G et al. Gastrointestinal tract specific gene GDDR inhibits the progression of gastric cancer in a TFF1 dependent manner. Mol Cell Biochem. 2012;359(1–2):369–74.CrossRefPubMedGoogle Scholar
  17. 17.
    Moss SF et al. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res. 2008;14(13):4161–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Du JJ et al. Down-regulated full-length novel gene GDDR and its effect on gastric cancer. Zhonghua Yi Xue Za Zhi. 2003;83(13):1166–8.PubMedGoogle Scholar
  19. 19.
    Menheniott TR, Kurklu B, Giraud AS. Gastrokines: stomach-specific proteins with putative homeostatic and tumor suppressor roles. Am J Physiol Gastrointest Liver Physiol. 2013;304(2):G109–21.CrossRefPubMedGoogle Scholar
  20. 20.
    Resnick MB et al. Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo. Gut. 2006;55(12):1717–24.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gibson CJ, Davids MS. BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res. 2015;21(22):5021–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Li Y et al. Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-kappaB signaling pathway both in vitro and in vivo. Tumour Biol 2015.Google Scholar
  23. 23.
    Zhang Z et al. MiR-429 induces apoptosis of glioblastoma cell through Bcl-2. Tumour Biol 2015.Google Scholar
  24. 24.
    Qiu MZ et al. Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. Tumour Biol. 2011;32(3):509–14.CrossRefPubMedGoogle Scholar
  25. 25.
    Parkin DM. International variation. Oncogene. 2004;23(38):6329–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Leung WK et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–87.CrossRefPubMedGoogle Scholar
  27. 27.
    Wong BC et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61(6):812–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Pan KF et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population. Int J Cancer. 2014;134(9):2118–25.CrossRefPubMedGoogle Scholar
  29. 29.
    Kim O et al. GKN2 contributes to the homeostasis of gastric mucosa by inhibiting GKN1 activity. J Cell Physiol. 2014;229(6):762–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Peterson AJ et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology. 2010;139(6):2005–17.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    He A et al. TLR4-MyD88-TRAF6-TAK1 complex-mediated NF-kappaB activation contribute to the anti-inflammatory effect of V8 in LPS-induced human cervical cancer SiHa cells. Inflammation 2015.Google Scholar
  32. 32.
    Postler TS, Ghosh S. Bridging the gap: a regulator of NF-kappaB linking inflammation and cancer. J Oral Biosci. 2015;57(3):143–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Tsumagari K et al. Simultaneous suppression of the MAP kinase and NF-kappaB pathways provides a robust therapeutic potential for thyroid cancer. Cancer Lett. 2015;368(1):46–53.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Xing R et al. GKN1 inhibits cell invasion in gastric cancer by inactivating the NF-kappaB pathway. Discov Med. 2015;19(103):65–71.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zhanwei Zhao
    • 1
  • Fei Wang
    • 1
  • Cheng Fang
    • 1
  • Gang Wang
    • 1
  • Jianbo Shuang
    • 1
  • Guanghui Chu
    • 1
  • Sijun Hu
    • 1
  • Lin Chen
    • 1
  • Jianjun Du
    • 1
  1. 1.State Key Laboratory of Cancer Biology and Xijing Hospital of Digestive DiseasesThe Fourth Military Medical UniversityXi’anChina

Personalised recommendations